Stay updated on Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial
Sign up to get notified when there's something new on the Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial page.

Latest updates to the Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe web page has removed significant details about a Phase 2 clinical trial for ARV-471 and anastrozole in post-menopausal women with ER+/HER2- breast cancer, including the study's goals and inclusion/exclusion criteria, while adding a new version identifier.SummaryDifference20%
- Check21 days agoChange DetectedThe web page has been updated from version 2.14.3 to version 2.14.4.SummaryDifference0.1%
- Check29 days agoChange DetectedThe web page has been updated from version 2.14.2 to version 2.14.3.SummaryDifference0.1%
- Check65 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check79 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference2%
- Check86 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
Stay in the know with updates to Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Postmenopausal Breast Cancer ARV-471 vs Anastrozole Clinical Trial page.